Evacetrapib

Description	Together with anacetrapib and dalcetrapib, evacetrapib is the third CETP inhibitor currently being investigated. Despite the problems with torcetrapib, it is thought that CETP inhibitors are still likely to be useful in the treatment of dyslipidemia and the prevention of cardiovascular disease.
Pathways	Protease/Metabolic Enzyme
Targets	CETP

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.